Literature DB >> 1854164

Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice.

J Gisby1, B J Wightman, A S Beale.   

Abstract

Experimental respiratory infections were established in mice by intranasal inoculation of Streptococcus pneumoniae. Inoculation of 10(7) CFU of either S. pneumoniae 1629 or S. pneumoniae 7 produced a fatal pneumonia in nontreated mice 2 to 3 days after infection. Oral therapy was commenced 1 h after infection and was continued three times a day for 2 days. The doses used in mice produced peak concentrations in serum and lung tissue similar to those measured in humans. Ciprofloxacin failed to eliminate either strain of pneumococcus from mouse lungs at any of the doses tested (40, 80, or 160 mg/kg of body weight) by the end of therapy (33 h). Mice that received ciprofloxacin at 160 mg/kg were clear of S. pneumoniae 7 5 days later, whereas persistence and regrowth of S. pneumoniae 1629 resulted in the death of 20% of animals treated with ciprofloxacin. Therapy with cefaclor (20 mg/kg) produced an effect similar to that of ciprofloxacin. In contrast, amoxicillin (10 and 20 mg/kg) and amoxicillin-clavulanic acid (10/5 and 20/10 mg/kg) were significantly (P less than 0.05) more effective in eliminating both strains of S. pneumoniae from the lungs by the end of therapy and, by 168 h, had prevented mortality in 80 to 100% of treated animals. The efficacy of ciprofloxacin against these experimental pneumococcal respiratory infections was poor, despite good penetration into lung tissue, and is a reflection of the low in vitro activity of the quinolone against S. pneumoniae, one of the most common pathogens in community-acquired pneumonia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1854164      PMCID: PMC245115          DOI: 10.1128/AAC.35.5.831

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia.

Authors:  B Cooper; M Lawlor
Journal:  Am J Med       Date:  1989-10       Impact factor: 4.965

Review 2.  A comprehensive review of the clinical pharmacology and pharmacokinetics of cefaclor.

Authors:  G D Sides; T R Franson; K A DeSante; H R Black
Journal:  Clin Ther       Date:  1988       Impact factor: 3.393

3.  Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa.

Authors:  D Honeybourne; J M Andrews; J P Ashby; R Lodwick; R Wise
Journal:  Thorax       Date:  1988-09       Impact factor: 9.139

4.  Use of oral ciprofloxacin in community-acquired pneumonia.

Authors:  C J Chrysanthopoulos; H P Bassaris
Journal:  J Chemother       Date:  1989-04       Impact factor: 1.714

5.  Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

6.  Cefixime versus amoxicillin/clavulanic acid in lower respiratory tract infections.

Authors:  H M Beumer
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-01

Review 7.  Quinolones in the treatment of bronchopulmonary infections.

Authors:  J P Thys
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

8.  Role of fluoroquinolones in lower respiratory tract infections.

Authors:  H Vellend
Journal:  Clin Invest Med       Date:  1989-02       Impact factor: 0.825

9.  Ciprofloxacin in the treatment of pneumonia.

Authors:  J A Ernst; E R Sy; H Colon-Lucca; N Sandhu; T Rallos; V Lorian
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

10.  Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.

Authors:  B I Davies; F P Maesen; C Baur
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

View more
  5 in total

1.  Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.

Authors:  Pierre Abgueguen; Esther Azoulay-Dupuis; Violaine Noel; Pierre Moine; Veronique Rieux; Bruno Fantin; Jean-Pierre Bedos
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

2.  Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects.

Authors:  J E Conte; J Golden; S Duncan; E McKenna; E Lin; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

Review 3.  Quinolones in the treatment of lower respiratory tract infections in adult patients.

Authors:  C Carbon
Journal:  Drugs       Date:  1993       Impact factor: 9.546

4.  Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.

Authors:  S P Bonacorsi; M R Scavizzi; A Guiyoule; J H Amouroux; E Carniel
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

5.  Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model.

Authors:  M C Sullivan; B W Cooper; C H Nightingale; R Quintiliani; M T Lawlor
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.